GlassScriptPhysician profile
Alexander Mauskop
NPI 1215194659
$70,598.83
in general payments reported to CMS, 2019-2025
31 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $17K · 2021: $32K · 2022: $18K · 2023: $1,733 · 2024: $223 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,100 · Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,100.00 |
| Food and Beverage | $1,019.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $31,693.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17,749.47 | 2022 | |
| Lundbeck LLC | $16,599.55 | 2020-2023 | Vyepti |
| Abbvie INC. | $1,289.16 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $640.48 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $228.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $228.81 | 2019-2020 | |
| Abbott Laboratories | $190.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $181.55 | 2019-2020 | |
| Shockwave Medical, INC | $181.50 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $169.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $138.24 | 2019-2020 | |
| Novo Nordisk INC | $131.81 | 2019-2020 | |
| Amgen INC. | $127.88 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.45 | 2019-2025 | Camzyos |
| Impel Pharmaceuticals INC. | $97.65 | 2022 | |
| Lilly USA, LLC | $96.03 | 2019-2024 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $85.76 | 2019 | |
| Revance Therapeutics, INC. | $84.72 | 2024 | Daxxify |
| Upsher-Smith Laboratories LLC | $83.59 | 2020-2021 | |
| Biotronik INC. | $52.93 | 2019-2020 | |
| Mdd US Operations, LLC | $47.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $33.55 | 2021 | |
| Allergan, INC. | $31.46 | 2019 | |
| Irhythm Technologies, INC. | $31.09 | 2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $24.58 | 2020 | |
| Astellas Pharma US INC | $24.09 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.98 | 2019 | |
| Pfizer INC. | $22.34 | 2019 | |
| Bausch Health US, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Mauskop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.